Lowest Price Guaranteed
Pages
266
Last Updated
September 2025
View Count
12579
Chapter 2 presents an executive summary of the report. It offers a high level view on the research and analysis presented in the report, highlighting where the new generation antibiotics market is headed in the mid-long term.
Chapter 3 provides a general introduction to antibiotics, featuring information on their serendipitous discovery, their use, a detailed classification of the various types of antibiotics based on multiple parameters and information on their respective mechanisms of action. Additionally, the chapter highlights the underlying concepts related to the development of antibiotic drug resistance and how it spreads. The chapter also includes a discussion on the most hazardous pathogen species, such as the ones categorized under ESKAPE pathogens and those considered as urgent threats. Further, it presents details on the global prevalence of antibiotic resistant disease, highlighting the geographies where they occur most frequently, and the important government initiatives undertaken to address this global threat.
Chapter 4 provides a comprehensive overview of the current landscape of the new generation antibiotics market. It includes information on potential drug candidates that are currently marketed and those that are in different stages of development (both clinical and preclinical / discovery). It presents a detailed analysis of the pipeline of products in this domain, including information on the most commonly targeted indications, current stage of development of pipeline molecules, highlighting their spectrum of activity, the drug class they represent and the key players involved in their development.
Chapter 5 presents detailed illustrations on active comparator studies of approved and phase III drugs that have been / are being developed for various indications, such as respiratory disorders (CAP, HAP / VAP), gastrointestinal disorders (cIAIs, CDIs), skin infections (ABSSSIs / cSSSIs), CRE infections and UTIs. The chapter includes a detailed bull’s eye analysis on the late stage clinical molecules and a grid analysis of the pipeline, highlighting the most popular infectious diseases against which new generation antibiotics are being developed. It also presents a detailed developer landscape, highlighting the start-ups, small / mid-sized companies and the pharma giants that are involved in this field.
Chapter 6 is focused on the new generation antibiotics that have been recently approved. It provides comprehensive profiles, containing a brief description of the drugs, geographical areas where they are approved, their respective mechanisms of action, dosage regimens, information on revenues generated on product sales and current status of development. In addition, the chapter also offers details on the recent collaborations that have been inked related to each of the profiled drugs.
Chapter 7 provides in-depth information on the antibiotics that are in phase III of clinical development. It features drug profiles highlighting relevant information on licensing, drug class, mechanism of action, route of administration, current status of development, key insights from clinical studies, recent collaborations and specific designations or statuses granted to each drug (if any).
Chapter 8 elaborates on the various alternative forms of treatment that are being explored to combat antibiotic drug resistance. These emerging therapies include teixobactin, anti-microbial peptides, antisense antibacterials, quorum sensing inhibition based therapies, nano-metals and anti-biofilm agents. The chapter provides brief overviews of the different types of therapies and details on their respective mechanisms of action.
Chapter 9 provides information on the most popular disease indications in this space. These include ABSSSI, CAP, CDI, IAI, HAP / VAP, and UTI. The chapter presents brief descriptions of the aforementioned diseases, their epidemiology and current treatment plans for each indication. In addition, the chapter highlights the names of the various pathogens that have been shown to cause these diseases. It also includes a detailed comparison of the dosage regimens of the approved drugs that are currently prescribed for the treatment of each of the aforementioned disease indications.
Chapter 10 provides a comprehensive market forecast analysis, highlighting the future potential of the market till 2026. The analysis takes into consideration the molecules that are approved and those that are in advanced stages of development (phase III, phase II/III and phase II). Projections of the future sales potential and growth opportunity are based on target patient populations, existing / future competition, likely adoption rates and the overall market size of each therapeutic area.
Chapter 11 summarizes the overall report. In this chapter, we have provided a recap of the key takeaways from the study and also presented our independent opinion based on the research and analysis described in the previous chapters.
Chapter 12 is a collection of interview transcripts of the discussions that were held with key stakeholders in this market. In this chapter, we have presented the details provided to us by Dr. Marilyn Bruno (CEO, Aequor), Dr. Mike Dawson (CEO, Cantab Anti-infectives), Dr. Kristin Thompson (Business Development Manager, Da Volterra), Elhan Webb (Business Development / Investor Relations, Morphochem) and Dr. Deborah A O'Neil (CEO & CSO, NovaBiotics).
Chapter 13 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.
Chapter 14 is an appendix, which provides the list of companies and organizations mentioned in the report.
1. PREFACE
1.1. Chapter Overview
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Classification of Bacteria: Gram-Positive and Gram-Negative
3.3. Antibiotics: A Brief History
3.4. Antibiotics: Definition and Use
3.5. Classification of Antibiotics
3.5.1. Broad Spectrum versus Narrow Spectrum
3.5.2. Bactericidal versus Bacteriostatic
3.6. The Concept of Antibiotic Drug Resistance
3.7. History of Development of Antibiotic Drug Resistance
3.8. Evolution of Antibiotic Drug Resistance in Gram-Positive and Gram-Negative Bacteria
3.9. Key Antibacterial Agents and their Mechanism of Action
3.9.1. Cell Wall Synthesis
3.9.1.1. β-lactam based Antibiotics
3.9.1.2. Vancomycin
3.9.2. Cell Membrane Synthesis
3.9.2.1. Polymyxins
3.9.2.2. Bacteriocin
3.9.3. Protein Synthesis
3.9.3.1. Macrolides
3.9.3.2. Aminoglycosides
3.9.3.3. Tetracyclines
3.9.4. Nucleic Acid Synthesis
3.9.4.1. DNA Gyrase: Quinolones
3.9.4.2. RNA Polymerase: Rifampin
3.9.4.3. Folate Synthesis: Sulfonamides and Trimethoprim
3.10. Antibiotic-Resistant Bacteria: ESKAPE Pathogens
3.11. Antibiotic-Resistant Bacteria: Urgent, Serious and Concerning Threats
3.11.1. Urgent Threat Bacteria
3.11.2. Serious Threat Bacteria
3.11.3. Concerning Threat Bacteria
3.12. Antibiotic Drug Resistance: Geographical Spread
3.13. Antibiotic Drug Resistance: Government Initiatives
4. ANTIBIOTIC DRUG RESISTANCE: DEVELOPMENT PIPELINE AND MARKET LANDSCAPE
4.1. Chapter Overview
4.2. New Generation Antibiotics: Development Pipeline
4.2.1. Distribution by Phase of Development
4.2.2. Distribution by Spectrum of Activity
4.2.3. Distribution by Urgent Threat
4.2.4. Distribution by Activity against ESKAPE Pathogen
4.2.5. Geographical Distribution of Industry Stakeholders
4.3. Antibiotic Drug Resistance: Alternative Therapies
5. CLINICAL DEVELOPMENT ANALYSIS AND KEY COMPARATOR STUDIES
5.1. Clinical Development Analysis: Spectrum of Activity and Target Bacterial Pathogen
5.2. Clinical Development Analysis: Developer Landscape
5.3. Clinical Development Analysis: Distribution by Highest Phase of Development and Indication
5.4. Analysis on Active Comparator Trials
5.4.1. ABSSSIs: Active Comparator Trials
5.4.2. CAP: Active Comparator Trials
5.4.3. HAP / VAP: Active Comparator Trials
5.4.4. cUTIs: Active Comparator Trials
5.4.5. Gastrointestinal Infections (cIAIs and CDIs): Active Comparator Trials
5.4.6. Infections Caused by CRE: Active Comparator Trials
6. NEW GENERATION ANTIBIOTICS: MARKETED DRUGS
6.1. Chapter Overview
6.2. Telavancin (Vibativ)
6.2.1. Drug Overview
6.2.2. Mechanism of Action
6.2.3. Drug Dosage and Administration
6.2.4. Historical Sales
6.2.5. Current Status of Development
6.2.6. Collaborations
6.3. Ceftaroline Fosamil (Teflaro / Zinforo)
6.3.1. Drug Overview
6.3.2. Mechanism of Action
6.3.3. Drug Dosage and Administration
6.3.4. Current Status of Development
6.3.5. Collaborations
6.4. Fidaxomicin (Dificid / Dificlir™)
6.4.1. Drug Overview
6.4.2. Mechanism of Action
6.4.3. Drug Dosage and Administration
6.4.4. Historical Sales
6.4.5. Current Status of Development
6.4.6. Collaborations
6.5. Ceftobiprole Medocaril (Zevtera / Zeftera / Mabelio)
6.5.1. Drug Overview
6.5.2. Mechanism of Action
6.5.3. Drug Dosage and Administration
6.5.4. Current Status of Development
6.5.5. Collaborations
6.6. Dalbavancin (Dalvance / Xydalba™)
6.6.1. Drug Overview
6.6.2. Mechanism of Action
6.6.3. Drug Dosage and Administration
6.6.4. Current Status of Development
6.6.5. Collaborations
6.7. Tedizolid Phosphate (Sivextro)
6.7.1. Drug Overview
6.7.2. Mechanism of Action
6.7.3. Drug Dosage and Administration
6.7.4. Current Status of Development
6.7.5. Collaborations
6.8. Oritavancin (Orbactiv / Nuvocid)
6.8.1. Drug Overview
6.8.2. Mechanism of Action
6.8.3. Drug Dosage and Administration
6.8.4. Current Status of Development
6.8.5. Collaborations
6.9. Ceftolozane-Tazobactam (Zerbaxa)
6.9.1. Drug Overview
6.9.2. Mechanism of Action
6.9.3. Drug Dosage and Administration
6.9.4. Current Status of Development
6.9.5. Historical Sales
6.9.6. Collaborations
6.10. Ceftazidime-Avibactam (Avycaz / Zavicefta)
6.10.1. Drug Overview
6.10.2. Mechanism of Action
6.10.3. Drug Dosage and Administration
6.10.4. Current Status of Development
6.10.5. Collaborations
7. NEW GENERATION ANTIBIOTICS: PHASE III DRUGS
7.1. Chapter Overview
7.2. Cadazolid: Current Status and Key Developments
7.3. Carbavance: Current Status and Key Developments
7.4. Cefilavancin: Current Status and Key Developments
7.5. CEM-102: Current Status and Key Developments
7.6. Delafloxacin: Current Status and Key Developments
7.7. Eravacycline: Current Status and Key Developments
7.8. Iclaprim: Current Status and Key Developments
7.9. Lefamulin: Current Status and Key Developments
7.10. Omadacycline: Current Status and Key Developments
7.11. Plazomicin: Current Status and Key Developments
7.12. Relebactam (Imipenem plus Cilastatin): Current Status and Key Developments
7.13. S-649266: Current Status and Key Developments
7.14. Sarecycline: Current Status and Key Developments
7.15. Solithromycin: Current Status and Key Developments
7.16. Zabofloxacin: Current Status and Key Developments
8. EMERGING THERAPIES TO COMBAT ANTIBIOTIC RESISTANCE
8.1. Chapter Overview
8.2. Teixobactin
8.2.1. Overview
8.2.2. Mechanism of Action
8.3. Antimicrobial Peptides
8.3.1. Overview
8.3.2. Classification of Antimicrobial Peptides
8.3.3. Mechanism of Action
8.3.4. Ctriporin: A Novel Antimicrobial Peptide
8.4. Antisense Antibacterials
8.4.1. Overview
8.4.2. Mechanism of Action
8.4.3. RNAP: Novel Target for Antisense Antibacterials
8.5. Quorum Sensing
8.5.1. Overview
8.5.2. Mechanism of Action
8.5.3. Inhibition of Quorum Sensing
8.6. Nano-Metals
8.6.1. Overview
8.6.2. Mechanism of Action
8.7. Restoration of β-Lactam Activity in MRSA
8.7.1. Overview
8.7.2. Mechanism of Action
8.8. Anti-Biofilm Agents
8.8.1. Overview
8.8.2. Mechanism of Action
9. KEY THERAPEUTIC AREAS
9.1. Chapter Overview
9.2. Acute Bacterial Skin and Skin Structure Infections (ABSSSIs)
9.2.1. Disease Description
9.2.2. Epidemiology
9.2.3. Current Treatment Plans
9.2.4. ABSSSIs:Dosage Regimens for Approved Drugs
9.3. Clostridium difficile Infections (CDIs)
9.3.1. Disease Description
9.3.2. Epidemiology
9.3.3. Current Treatment Plans
9.3.4. CDIs:Dosage Regimens for Approved Drugs
9.4. Complicated Intra-Abdominal Infections (cIAIs)
9.4.1. Disease Description
9.4.2. Epidemiology
9.4.3. Current Treatment Plans
9.4.4. cIAIs:Dosage Regimens for Approved Drugs
9.5. Complicated Urinary Tract Infections (cUTIs)
9.5.1. Disease Description
9.5.2. Epidemiology
9.5.3. Current Treatment Plans
9.5.4. cUTIs:Dosage Regimens for Approved Drugs
9.6. Hospital-acquired / Ventilator-acquired / Community-acquired Pneumonia (HAP / VAP / CAP)
9.6.1. Disease Description
9.6.2. Epidemiology
9.6.3. Current Treatment Plans
9.6.4. HAP / CAP / VAP: Dosage Regimens for Approved Drugs
10. MARKET FORECAST AND OPPORTUNITY ANALYSIS
10.1. Chapter Overview
10.2. Forecast Methodology
10.3. New Generation Antibiotics Market: Key Assumptions
10.4. Overall New Generation Antibiotics Market, 2016-2026
10.4.1. New Generation Antibiotics Market, 2016-2026: Distribution by Disease Area
10.4.1.1. New Generation Antibiotics Market in CAP, 2016-2026
10.4.1.2. New Generation Antibiotics Market in ABSSSIs, 2016-2026
10.4.1.3. New Generation Antibiotics Market in cUTIs, 2016-2026
10.4.1.4. New Generation Antibiotics Market in HAP / VAP, 2016-2026
10.4.1.5. New Generation Antibiotics Market in cIAIs, 2016-2026
10.4.1.6. New Generation Antibiotics Market in CDIs, 2016-2026
11. CONCLUSION
11.1. Antibiotic Drug Resistance: An Impending Threat to Global Healthcare
11.2. Novel Antibiotic Classes with Innovative Mechanisms of Action are Currently Being Investigated
11.3. An Active Support from Regional Governments has Encouraged Clinical Development
11.4. Highly Potent Strains of MDR Bacteria have Evolved to Cause Potentially Life Threatening Diseases
11.5. The New Generation Antibiotics Market is Projected to Grow at an Aggressive Pace over the Next Decade
12. INTERVIEW TRANSCRIPTS
12.1. Chapter Overview
12.2. Interview Transcript 1: Dr. Marilyn Bruno, CEO, Aequor
12.3. Interview Transcript 2: Dr. Mike Dawson, CEO, Cantab Anti-infectives
12.4. Interview Transcript 3: Dr. Kristin Thompson, Business Development Manager, Da Volterra
12.5. Interview Transcript 4: Dr. Deborah A O'Neil, CEO & CSO, NovaBiotics
12.6. Interview Transcript 5: Elhan Webb, CFA, Morphochem
13. APPENDIX 1: TABULATED DATA
14. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Figure 3.1 Patients with High Risk of Infection
Figure 3.2 Key Milestones for Emergence of Antibiotic Resistance
Figure 3.3 Antibiotics: Important Targets and Drug Classes
Figure 3.4 Sulfonamides and Trimethoprim: Target Enzymes in the Folic Acid Metabolic Pathway
Figure 3.5 Antibiotic-Resistant Bacteria: Urgent, Serious and Concerning Threats
Figure 4.1 New Generation Antibiotics Development Pipeline: Distribution by Phase of Development
Figure 4.2 New Generation Antibiotics Development Pipeline: Distribution by Spectrum of Activity
Figure 4.3 New Generation Antibiotics Development Pipeline: Distribution by Activity against Urgent Threats
Figure 4.4 New Generation Antibiotics Development Pipeline: Distribution by Type of Urgent Threat Bacteria Targeted
Figure 4.5 New Generation Antibiotics Development Pipeline: Distribution by Activity against ESKAPE Pathogens
Figure 4.6 New Generation Antibiotics: Geographical Distribution of Key Industrial Players
Figure 5.1 New Generation Antibiotics: Grid Analysis, Distribution by Target Bacterial Pathogen, Spectrum of Activity and Phase of Development
Figure 5.2 New Generation Antibiotics: Landscape Analysis, Distribution by Developer and Phase of Development
Figure 5.3 New Generation Antibiotics: Bull’s Eye Analysis, Distribution by Highest Phase of Development and Indication
Figure 5.4 ABSSSIs: Active Comparator Trials
Figure 5.5 CAP: Active Comparator Trials
Figure 5.6 HAP / VAP: Active Comparator Trials
Figure 5.7 cUTIs: Active Comparator Trials
Figure 5.8 Gastrointestinal Infections (cIAIs and CDIs): Active Comparator Trials
Figure 5.9 Infections Caused by CRE: Active Comparator Trials
Figure 8.1 Antimicrobial Peptides: Mechanisms of Action
Figure 8.2 Antisense Antibacterials: Mechanism of Action
Figure 8.3 The Process of Quorum Sensing
Figure 8.4 Quorum Sensing Inhibition: Mechanism of Action
Figure 8.5 Nanotechnology in Healthcare: Applications
Figure 8.6 Nano-Metals as Antibacterial Agents: Mechanism of Action
Figure 8.7 β-lactamase Mediated Antibiotic Resistance in MRSA
Figure 8.8 Restoration of β-lactam Activity in MRSA
Figure 8.9 Natural Anti-Biofilm Agents
Figure 9.1 cIAIs: Clinical Symptoms
Figure 9.2 Pathophysiology of cUTIs
Figure 10.1 New Generation Antibiotics Market, 2016-2026, Base Case (USD Billion)
Figure 10.2 New Generation Antibiotics Market (USD Billion): Distribution by Disease Area, 2026
Figure 10.3 CAP: New Generation Antibiotics Market, Base Case (USD Million), 2016, 2021, 2026
Figure 10.4 ABSSSIs: New Generation Antibiotics Market, Base Case (USD Million), 2016, 2021, 2026
Figure 10.5 cUTIs: New Generation Antibiotics Market, Base Case (USD Million), 2016, 2021, 2026
Figure 10.6 HAP / VAP: New Generation Antibiotics Market, Base Case (USD Million), 2016, 2021, 2026
Figure 10.7 cIAIs: New Generation Antibiotics Market, Base Case (USD Million), 2016, 2021, 2026
Figure 10.8 CDIs: New Generation Antibiotics Market, Base Case (USD Million), 2016, 2021, 2026
Figure 11.1 New Generation Antibiotics Market Summary, 2016, 2021 and 2026 (USD Million)
Table 3.1 Gram-Positive and Gram-Negative Bacteria: Key Differences
Table 3.2 Antibiotics: Common Instances of Misuse
Table 3.3 ESKAPE Pathogens: Hospital-Acquired Infections
Table 3.4 Urgent Threat Bacteria: Epidemiology of Infectious Agents
Table 3.5 Serious Threat Bacteria: Epidemiology of Infectious Agents
Table 3.6 Concerning Threat Bacteria: Epidemiology of Infectious Agents
Table 3.7 Projects Funded by BARDA for Antibiotic Development
Table 4.1 New Generation Antibiotics Development Pipeline: Infections Caused by Gram-Positive Bacteria
Table 4.2 New Generation Antibiotics Development Pipeline: Infections Caused by Gram-Negative Bacteria
Table 4.3 New Generation Antibiotics Development Pipeline: Infections Caused by Gram-Negative / Positive Bacteria
Table 4.4 New Generation Antibiotics Development Pipeline: Alternative Therapies
Table 6.1 New Generation Antibiotics: Approved Drugs (2010 onwards)
Table 6.2 Telavancin: Dosage Regimen
Table 6.3 Telavancin: Current Status of Development
Table 6.4 Telavancin: Current Product Development Partners
Table 6.5 Telavancin: Recent Collaborations
Table 6.6 Ceftaroline Fosamil: Dosage Regimen
Table 6.7 Ceftaroline Fosamil: Current Status of Development
Table 6.8 Ceftaroline Fosamil: Current Product Development Partners
Table 6.9 Ceftaroline Fosamil: Recent Collaborations
Table 6.10 Fidaxomicin: Dosage Regimen
Table 6.11 Fidaxomicin: Current Status of Development
Table 6.12 Fidaxomicin: Current Product Development Partners
Table 6.13 Fidaxomicin: Recent Collaborations
Table 6.14 Ceftobiprole Medocaril: Dosage Regimen
Table 6.15 Ceftobiprole Medocaril: Current Status of Development
Table 6.16 Ceftobiprole Medocaril: Current Product Development Partners
Table 6.17 Ceftobiprole Medocaril: Recent Collaborations
Table 6.18 Dalbavancin: Dosage Regimen
Table 6.19 Dalbavancin: Current Status of Development
Table 6.20 Dalbavancin: Current Product Development Partners
Table 6.21 Dalbavancin: Recent Collaborations
Table 6.22 Tedizolid Phosphate: Dosage Regimen
Table 6.23 Tedizolid Phosphate: Current Status of Development
Table 6.24 Tedizolid Phosphate: Current Product Development Partners
Table 6.25 Tedizolid Phosphate: Recent Collaborations
Table 6.26 Oritavancin: Dosage Regimen
Table 6.27 Oritavancin: Current Status of Development
Table 6.28 Oritavancin: Current Product Development Partners
Table 6.29 Oritavancin: Recent Collaborations
Table 6.30 Ceftolozane-Tazobactam: Dosage Adjustments
Table 6.31 Ceftolozane-Tazobactam: Dosage Regimen
Table 6.32 Ceftolozane-Tazobactam: Current Status of Development
Table 6.33 Ceftolozane-Tazobactam: Current Product Development Partners
Table 6.34 Ceftolozane-Tazobactam: Recent Collaborations
Table 6.35 Ceftazidime-Avibactam: Dosage Adjustments
Table 6.36 Ceftazidime-Avibactam: Dosage Administration
Table 6.37 Ceftazidime-Avibactam: Current Status of Development
Table 6.38 Ceftizidime-Avibactam: Current Product Development Partners
Table 6.39 Ceftazidime-Avibactam: Recent Collaborations
Table 7.1 New Generation Antibiotics: Phase III Drugs
Table 7.2 Drug Profile: Cadazolid
Table 7.3 Drug Profile: Carbavance®
Table 7.4 Drug Profile: Cefilavancin
Table 7.5 Drug Profile: CEM-102
Table 7.6 Drug Profile: Delafloxacin
Table 7.7 Drug Profile: Eravacycline
Table 7.8 Drug Profile: Iclaprim
Table 7.9 Drug Profile: Lefamulin
Table 7.10 Drug Profile: Omadacycline
Table 7.11 Drug Profile: Plazomicin
Table 7.12 Drug Profile: Relebactam (Imipenem plus Cilastatin)
Table 7.13 Drug Profile: S-649266
Table 7.14 Drug Profile: Sarecycline
Table 7.15 Drug Profile: Solithromycin
Table 7.16 Drug Profile: Zabofloxacin
Table 8.1 Nano-Metals as Antimicrobial Agents: Mechanism of Action
Table 9.1 Key Indications and Causative Pathogen
Table 9.2 ABSSSIs: Dosage Regimen for Approved Drugs
Table 9.3 CDIs: Dosage Regimen for Approved Drugs
Table 9.4 cIAIs: Current Treatment Plans
Table 9.5 cIAIs: Dosage Regimen for Approved Drugs
Table 9.6 cUTIs: Dosage Regimen for Approved Drugs
Table 9.7 HAP / CAP / VAP: Dosage Regimen for Approved Drugs
Table 10.1 New Generation Antibiotics Market: List of Forecasted Molecules (Approved / Phase III / Phase II)
Table 10.2 Key Resistant Bacterial Infections : Estimated Market Growth Rate
Table 10.3 Key Resistant Bacterial Infections: Estimated Penetration (By 2026)
Table 10.4 Previous Generation Popular Antibiotics: Sales (USD Million)
Table 13.1 New Generation Antibiotics Development Pipeline: Distribution by Phase of Development
Table 13.2 New Generation Antibiotics Development Pipeline: Distribution by Activity against ESKAPE Pathogens
Table 13.3 New Generation Antibiotics Development Pipeline: Distribution by Activity against Urgent Threats
Table 13.4 New Generation Antibiotics Development Pipeline: Distribution by Type of Urgent Threat Bacteria Targeted
Table 13.5 New Generation Antibiotics Market, 2016-2026, Base Case (USD Billion)
Table 13.6 New Generation Antibiotics Market, 2016-2026, Optimistic Case (USD Billion)
Table 13.7 New Generation Antibiotics Market, 2016-2026, Conservative Case (USD Billion)
Table 13.8 New Generation Antibiotics Market (USD Million): Distribution by Disease Area, 2026
Table 13.9 CAP: New Generation Antibiotics Market (USD Million), Base Case 2016, 2021, 2026
Table 13.10 CAP: New Generation Antibiotics Market (USD Million), Optimistic Case 2016, 2021, 2026
Table 13.11 CAP: New Generation Antibiotics Market (USD Million), Conservative Case 2016, 2021, 2026
Table 13.12 ABSSSIs: New Generation Antibiotics Market (USD Million), Base Case 2016, 2021, 2026
Table 13.13 ABSSSIs: New Generation Antibiotics Market (USD Million), Optimistic Case 2016, 2021, 2026
Table 13.14 ABSSSIs: New Generation Antibiotics Market (USD Million), Conservative Case 2016, 2021, 2026
Table 13.15 cUTIs: New Generation Antibiotics Market (USD Million), Base Case 2016, 2021, 2026
Table 13.16 cUTIs: New Generation Antibiotics Market (USD Million), Optimistic Case 2016, 2021, 2026
Table 13.17 cUTIs: New Generation Antibiotics Market (USD Million), Conservative Case 2016, 2021, 2026
Table 13.18 HAP / VAP: New Generation Antibiotics Market (USD Million), Base Case 2016, 2021, 2026
Table 13.19 HAP / VAP: New Generation Antibiotics Market (USD Million), Optimistic Case 2016, 2021, 2026
Table 13.20 HAP / VAP: New Generation Antibiotics Market (USD Million), Conservative Case 2016, 2021, 2026
Table 13.21 cIAIs: New Generation Antibiotics Market (USD Million), Base Case 2016, 2021, 2026
Table 13.22 cIAIs: New Generation Antibiotics Market (USD Million), Optimistic Case 2016, 2021, 2026
Table 13.23 cIAIs: New Generation Antibiotics Market (USD Million), Conservative Case 2016, 2021, 2026
Table 13.24 CDIs: New Generation Antibiotics Market (USD Million), Base Case 2016, 2021, 2026
Table 13.25 CDIs: New Generation Antibiotics Market (USD Million), Optimistic Case 2016, 2021, 2026
Table 13.26 CDIs: New Generation Antibiotics Market (USD Million), Conservative Case 2016, 2021, 2026
Table 13.27 New Generation Antibiotics Market Summary, 2016, 2021, 2026 (USD Million)
The following companies and organizations have been mentioned in the report.